Please provide your email address to receive an email when new articles are posted on . Wainua has received regulatory approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis.

This page lists all known medications that could potentially lead to 'Polyneuropathy' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

Since 1995 I have had the interesting experience of working as a neurologist in a large state prison whose primary mission is to provide medical care to inmates. A large proportion of my practice ...

– EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo – CARLSBAD, ...

A significant proportion of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and dysautonomia may have potentially treatable underlying autoimmune-associated small-fiber ...

Hereditary transthyretin amyloidosis (hATTR) is a rare inherited disorder that gets worse over time. It often affects the nerves, heart, liver, and kidneys, but it can also affect other organs.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among adults with type 2 diabetes, those reporting ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

Polyneuropathy is one of the most common complications in people with diabetes. First symptoms are often pins-and-needles sensations in the feet. Although polyneuropathy is present in about 30 percent ...